phase readout
saveNCT05524883: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
ACTIVE_NOT_RECRUITINGupdated 21h ago
community read0 votes
Sponsor: Dyne Therapeutics. Phase: PHASE1. Conditions: Duchenne Muscular Dystrophy (DMD)
view source ↗
comments(0)
5-min edit window · permanent after that